there was a 2007 paper that said the test was no good ... a 2013 paper that said it is a good tool for ruling out .. But, i think the paper I referenced above is most unbiased and up to date
you need to wait out this correction ... then it will go over$10 ... zenpad S is coming out this month and if review of picture quality is talked about, then $10 s very cheap ... So far, there is no good review out there
this paper is very encouraging for AKER, rapid PIFA , heparin test
hope i can post it
I did most of buying from 8 to 10 cents .. So, don't put your hopes too high for a run up .. LoL
What was the cash loss in most recent quarter ... They lost $750,000, but i think about $250,00 is non-cash .. am i correct
I like the facts that gross margins going up, expense control and revenue stablizing and maybe growing
It still has high chance of BK, but if this new CEO can continue executing as he has been, upside to $1 is liekly
This time around, pxlw is leader with the only chip out there with a 1 year lead. I am not sure who is selling here, but given it is run up from $4.5 to here, profit taking is not surprising
which we will learn in Nov ... Q3 will show impact of most of the 10 sales force hired Jan to May. Also, it should show some of the transition of past customers to the new higher pricing. We should also hear on China and EU sales of Hep test. Also, prior to CC, we may hear about the breath Ketone test for Diabetics.
So, my guess is that either this stock will finally break out around Q3 CC, or it never will.
As always, time will tell
The main reason this went to 30 cents were warrant B.
For warrant B holders, it is a bit of chess game .. as price goes down, they can convert more and own more shares .. as price goes up, their window of owning more shares diminishes
At 27 to 30 cents, nearly 175M shares have been traded, which suggests to me that most of warrant B holders that wanted to convert have converted.
Selling is near over and once price goes back uo, it could quickly go to 50 cents
is time to buy ... bad news from greek makes it even better
Darren already told you the $60M will be exceeded by a large margin as they are now selling all hardware and not just keyboard .. also they have the co-publish role .. market cap of $30M to $35M is cheap
yes .. typo ... June 2015
Aker has had poor execution since ever ... They launched pifa/pluss in late 2011 and Fisher just added it in early 2014 .. Having said that, they are taking good bold moves (2.5 times price increase !!, and adding 8 sales guys), but street is in the show me to believe you attitude
Will these moves pay off? We will learn more from the November CC ... I like to see good size insider purchases prior to the Nov CC
if all is well, this should fly come November (easy over $15), given there are only 5 million shares outstanding .. if not, this will go to $3
24 full-time equivalent employees,
6 in research and development,
3 in general and administrative,
4 in sales and marketing and
11 in direct and indirect manufacturing.
31 full-time equivalent employees,
9 in research and development,
4 in general and administrative,
7 in sales and marketing and
11 in direct and indirect manufacturing.
15 in sales and marketing (8 new hires in US for Hep sales)
Excluding RB4, FY 2016 should be same r better
RB4 could gernate sales of $50M to $200M (depending on who you ask)
So, $10M to $40M dropping to EBITDA or 14 cents to 55 cents !!!!
Main point was for the 12 months, operating loss/income was break even ... Last FY was the low
Q1 was terrible with $2.5M operating loss, but was expected and behind us
Should move up from here
i would say wait till Q2 results come out .. Breakout is after Q3 comes out ...
also google oxford univ findings that they have dev diabetics using ketone in breath ... AKER has patent on the technique and is coming out with the only breath test ..
too much going on here and to many eye on this .. the only negative is the snake oil salesman way of Aker ..
Will increase the $350k quarterly revenue to over $2M .. or above break even for USA hep allergy test
Everything else goes to bottom line with a 70% margin and no taxes for first $80M of profit !
these prices are absolute steal ..
Q1 was the bottom ... revenue will build quarter after quarter as price increase and increased sales force are phased in
good work capezoios5678 ... the more important question is what portion of HIT tests are done for critical care or emergency. As you point out, this is the portion that would make most sense to use a rapid test ...
I am guessing about 25% which would bring average hospital tests from 4 million HIT test to 1 million tests or average of $20,000 per hospital with $100 per test
oilman .. you are a good trader and you have been in and out gluu too .. this is going double digits soon .. you know it and i know it .. rest is just cup and soup
Q2 2015 ... $474,000
Q3 2015 ... $931,000
Q4 2015 ... $1,429,000
Q1 2016 ... $1,941,000
Q2 2016 ... $2,425,000
150 hospitals as of Q1 under old pricing
12 month to change existing hospitals of 150 to the new increased pricing
$25k per hospital spend on new increased pricing.
adding 15 new hospitals a month with 5 sales force and 30 with 10 sales force and 3 months lag from date of hire